This is a Validated Antibody Database (VAD) review about human IGFBP4, based on 3 published articles (read how Labome selects the articles), using IGFBP4 antibody in all methods. It is aimed to help Labome visitors find the most suited IGFBP4 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
IGFBP4 synonym: BP-4; HT29-IGFBP; IBP4; IGFBP-4; insulin-like growth factor-binding protein 4; IBP-4; IGF-binding protein 4

Hytest
mouse monoclonal (IBP3)
  • ELISA; human
Hytest IGFBP4 antibody (HyTest Ltd, 4IGF4 IBP3) was used in ELISA on human samples . J Clin Endocrinol Metab (2015) ncbi
mouse monoclonal (IBP182)
  • ELISA; human
Hytest IGFBP4 antibody (HyTest Ltd, 4IGF4 IBP182) was used in ELISA on human samples . J Clin Endocrinol Metab (2015) ncbi
Invitrogen
rabbit polyclonal
  • western blot; human; fig 3
In order to examine the effects of brusatol on the cellular proteome in a mutant non-small cell lung cancer cell line, Invitrogen IGFBP4 antibody (Thermo Fisher Scientific, PA5-C25925) was used in western blot on human samples (fig 3). Mol Cell Proteomics (2016) ncbi
R&D Systems
goat polyclonal
  • western blot; baboons; 1:2000; fig 2
R&D Systems IGFBP4 antibody (R&D, AF804) was used in western blot on baboons samples at 1:2000 (fig 2). Int J Obes (Lond) (2014) ncbi
Articles Reviewed
  1. Vartanian S, Ma T, Lee J, Haverty P, Kirkpatrick D, Yu K, et al. Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis. Mol Cell Proteomics. 2016;15:1220-31 pubmed publisher
  2. Hjortebjerg R, Tarnow L, Jorsal A, Parving H, Rossing P, Bjerre M, et al. IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy. J Clin Endocrinol Metab. 2015;100:3032-40 pubmed publisher
  3. Tchoukalova Y, Krishnapuram R, White U, Burk D, Fang X, Nijland M, et al. Fetal baboon sex-specific outcomes in adipocyte differentiation at 0.9 gestation in response to moderate maternal nutrient reduction. Int J Obes (Lond). 2014;38:224-30 pubmed publisher